Developmental Funds

描述（由申请人提供）： 发展基金科的介绍计划。由于本次提交是一个竞争性的 为了更新，我们将首先介绍一个简短的背景，描述我们的发展基金是如何使用的（以及目前正在使用的）。我们相信“业绩记录”是发展基金成功的最佳指标。因此，将在本届国际委员会会议期间总结发展基金的赠款。 我们每年资助四个发展基金项目，每个项目50，000美元。假设第一年取得进展，项目为期两年。我们错开项目;在任何一年，两个项目将在第一年，两个将在第二年。我们最近选择了项目10和11作为本（05）年度的第一年资助项目。本节以简短的RO-1申请格式介绍了这些申请。它们将在下一个ICMIC供资周期获得第二年的供资。因为我们有一个机制，选择发展项目，每年五月，我们包括两个“被命名”的项目，将被选为明年的初步资金。在2002年的比赛中，我们有三个项目，我们认为是非凡的。因此，我们当年利用机构资金资助了三个发展项目。 加州大学洛杉矶分校琼森综合癌症中心和医学院已分别同意将每年50，000美元承诺的一部分用于额外的分子成像发展基金项目。虽然该项目将接受癌症中心种子资助委员会（JCCC）和斯坦-奥本海默审查委员会（SOM）的内部审查，但Gasson博士和罗马博士已同意为此目的“指定”资金--接受内部同行审查。

DESCRIPTION (Provided by applicant): Plan of presentation for the Developmental Fund Section. Since this submission is a competitive renewal, we will first present a brief Background to describe how our Developmental Funds have been (and are currently being) used. We believe the "track record" is the best indicator of success for Developmental Funds. Consequently, summaries of Developmental Fund awards during the current ICMIC will follow. We support four Developmental Fund Projects annually, at $50,000 per project. Projects are for two years, assuming progress in the first year. We stagger projects; in any year, two projects will be in Year 1, and two will be in Year 2. We recently selected Projects 10 and 11 for their first year of funding during the current (05) year. They are presented, in an abbreviated RO-1 application format in this section. They will receive their second year of funding in the next ICMIC funding cycle. Because we have a mechanism in place for selecting Developmental Projects each May, we include two "to be named" projects to be selected next year for initial funding. In the 2002 competition we had three projects we felt were extraordinary. As a result, we funded three Developmental Projects that year, using Institutional funds. The UCLA Jonsson Comprehensive Cancer Center and the School of Medicine have each agreed to put up a portion of an annual $50,000 commitment to an additional Molecular Imaging Developmental Fund project. While the project will be subject to internal review by the Cancer Center Seed Grant committee (JCCC) and the Stein-Oppenheimer review committee (SOM), Drs. Gasson and Rome have agreed to "earmark" funds for this purpose - subject to internal peer review.